FDA Approvals, Successful Product Launches, Upcoming Earnings Schedules and Quarterly Financial Results - Research Report on Pfizer, Mettler-Toledo, Arena, Wright Medical, and Ophthotech PR Newswire NEW YORK, November 7, 2013 NEW YORK, November 7, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Mettler-Toledo International Inc. (NYSE: MTD), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), Wright Medical Group, Inc. (NASDAQ: WMGI), and Ophthotech Corporation (NASDAQ: OPHT). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Pfizer Inc. Research Report On November 4, 2013, Pfizer Inc. (Pfizer) announced that the FDA has approved a Prior Approval Supplement for EMBEDA (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CII. The Company informed that the Prior Approval Supplement included an update to the EMBEDA manufacturing process, addressing the pre-specified stability requirement that led to the voluntary recall of EMBEDA from the market in March 2011. Pfizer expects product availability in Q2 2014. The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/d702_PFE] Mettler-Toledo International Inc. Research Report On October 22, 2013, Mettler-Toledo Thornton, a division of Mettler-Toledo International Inc., announced the launch of the Pure Water Optical Dissolved Oxygen (ODO) Sensor. The Company informed that when paired with the Thornton M800 transmitter, the ODO Sensor provides high accuracy, fast response, and increased stability in demanding low ppb-level applications. Commenting on the launch, Christie Martin, Global Product Manager of Mettler-Toledo Thornton said, "The Pure Water Optical DO Sensor has a 33% faster response time over competitive optical models and is six times faster than traditional polarographic sensors, making it the fastest ODO measurement available on the market today." The Full Research Report on Mettler-Toledo International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/ac69_MTD] Arena Pharmaceuticals, Inc. Research Report On October 30, 2013, Arena Pharmaceuticals, Inc. (Arena) announced that it will release its Q3 2013 financial results, as well as provide a corporate update, on November 7, 2013, after the NASDAQ Global Select Market closes. On the same day, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT. The Full Research Report on Arena Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/6a95_ARNA] Wright Medical Group, Inc. Research Report On November 4, 2013, Wright Medical Group, Inc. (Wright Medical) reported its Q3 2013 financial results. During the quarter, the Company's net sales increased 13.3% YoY to $57.6 million. Q3 2013 net loss was $130.0 million, or $2.80 per diluted share, compared with a net loss of $5.3 million, or $0.14 per diluted share, in Q3 2012. "Notably, we were able to accelerate our growth rate in our U.S. foot and ankle business despite the ongoing transition activities as a result of the MicroPort transaction," said Robert Palmisano, President and CEO of Wright Medical. "We were pleased to see another quarter of strong international growth with positive progress in market development in several key countries. In addition, our recent agreement to acquire Biotech International represents another important step in the transformation of our business to a dedicated Extremities-Biologics company exclusively focused on extending our leadership position in this fast growing and underpenetrated market and is an important addition from which our international business can continue to grow." The Full Research Report on Wright Medical Group, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/1782_WMGI] OphthotechCorporation Research Report On October 30, 2013, Ophthotech Corporation (Ophthotech) announced that it will release its Q3 2013 financial results on November 13, 2013, before the US financial markets open. On the same day, the Company will host a conference call at 8:30 a.m. ET to discuss the results, as well as to provide a corporate update. The Full Research Report on Ophthotech Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/91ff_OPHT] EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. http://www.AnalystsCorner.com SOURCE Analysts' Corner Contact: Media Contact: Joe Thomas, +1-310-496-8071 (North America)
FDA Approvals, Successful Product Launches, Upcoming Earnings Schedules and Quarterly Financial Results - Research Report on
Press spacebar to pause and continue. Press esc to stop.